Blc.Bk

BLC.BK maintains a relatively strong liquidity position, with a current ratio of 2.01, indicating the company can cover its short-term liabilities with its short-term assets. However, the company's free cash flow is negative at -559.93 million THB, primarily due to a capital expenditure of -682.87 million THB, which suggests significant reinvestment in the business. The liquidity risk is rated as medium, reflecting the negative net cash position after subtracting total debt.

In terms of profitability, BLC.BK reports a return on equity (ROE) of 10.43% and a return on assets (ROA) of 7.31%, both of which are strong indicators of efficient use of equity and assets. The company's operating income of 228.83 million THB and net income of 173.02 million THB reflect a healthy margin, though the gross profit margin of 30.0% is in line with industry norms.

Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data. However, the business operates within the pharmaceuticals industry, which is typically characterized by high R&D intensity and long product development cycles. The company's exposure to geographic and segment-specific risks remains opaque without further disclosure.

The company's growth trajectory is not explicitly outlined in the available data, but the significant capital expenditure suggests a strategy of expansion or modernization. The outlook for the current fiscal year is not provided, but the company's financial performance indicates a stable operating environment.

Risk factors include a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 0.13 suggests a conservative capital structure, and the dilution risk is assessed as low, with no near-term pressure for equity issuance. The risk assessment does not indicate any significant regulatory or geopolitical risks specific to the company's operations.

Recent events, including filings and transcripts, are not detailed in the available data. The company's financial statements and risk assessment are based on the latest available data from verified market sources.